Clinical Implications of Abnormalities of Chromosomes 1 and 13 in Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|109|3|129-136

ISSN： 0001-5792

Source： Acta Haematologica, Vol.109, Iss.3, 2003-05, pp. : 129-136

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk Stratification Model in Elderly Patients with Multiple Myeloma: Clinical Role of Magnetic Resonance Imaging Combined with International Staging System and Cytogenetic Abnormalities

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-03 ,pp. : 7-16

Karger

Access to resources Recommend Favorite

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma

By  

Oncology, Vol. 87, Iss. 4, 2014-07 ,pp. : 224-231

Karger

Access to resources Recommend Favorite

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 202-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 41-51

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multiple myeloma

By  

TRENDS IN UROLOGY AND MEN'S HEALTH, Vol. 6, Iss. 1, 2015-01 ,pp. : 31-34

John Wiley & Sons Inc

Access to resources Recommend Favorite